Price range: $68.95 through $540.00
All products sold on this website are intended for research and identification purposes only and are not intended for human dosing, injections, or ingestion. These products are not FDA-approved to diagnose, treat, cure, or prevent any disease. By purchasing, you certify they will be used solely for legitimate laboratory research and not for human or animal consumption.
IGF-1 LR3 is an 83-amino acid synthetic polypeptide engineered to overcome limitations of native IGF-1 through two strategic modifications: glutamic acid-to-arginine substitution at position 3 and addition of a 13-residue N-terminal extension (MFPAMPLSSLFVN). These alterations reduce binding affinity for IGFBPs by approximately 100-fold while maintaining full target receptor activation capacity, resulting in increased bioavailability and extended half-life compared to native IGF-1. Research models examine its activation of tyrosine kinase signaling, downstream PI3K-Akt and Ras-MAPK pathways, effects on substrate uptake in experimental models, protein synthesis stimulation, and molecular proliferation in laboratory settings.
Francis et al. (1992). Castellino et al. (1992).
IGF-1 LR3 has been extensively studied in molecular signaling and pathway research, with investigations focusing on receptor-mediated signaling cascades, anabolic dynamics, substrate utilization, and molecular remodeling in various experimental models. Studies examine both its enhanced pharmacokinetic properties and downstream molecular responses.
Key Areas of Research:
Signaling: PI3K-Akt, MAPK-ERK, tyrosine kinase
Substrate: Uptake dynamics, lipid pathways, amino acid
Anabolic: Protein synthesis, proliferation, nitrogen
Molecular: Differentiation, survival signaling, viability
Together, these investigations demonstrate IGF-1 LR3’s potent activation of signaling pathways. As a modified IGF-1 analog with reduced IGFBP binding, LR3 provides a research framework for examining target receptor biology, anabolic signaling mechanisms, and downstream pathway characterization in diverse experimental systems.
Francis et al., Journal of Molecular Endocrinology, 1992
Castellino et al., Biochemical and Biophysical Research Communications, 1992
And be the first to hear about our new product drops!
By accessing this website, you acknowledge and agree to the following:
All products sold on this site are intended strictly for laboratory research purposes only. These products are NOT for human consumption, medical use, or veterinary use.
By proceeding, you confirm that:
We do not make any claims regarding the safety, efficacy, or suitability of these products for any specific use.
Any misuse, improper handling, or use outside of intended research purposes is strictly prohibited and is the sole responsibility of the purchaser.
